LAGUNA HILLS, CA--(Marketwired - March 26, 2014) -
Itonis, Inc. (PINKSHEETS: ITNS
) today issued the following update to its shareholders:
The Company recently announced that it had entered into a letter of intent to license a proprietary mobile app from MyECheck, Inc. to facilitate point of purchase transactions for medical marijuana, gambling and general retail sales. We are on track to finalize the licensing details soon. Through our pharmaceutical relationships, we noticed an unmet demand regarding medical marijuana and the point of sales from medical suppliers. We believe that there is a significant revenue opportunity in addressing this demand with MyECheck's proprietary payment app and connecting it to the medical marijuana sector.
We also announced that Dr. Charles Hensley approved the Emesyl™ nausea remedy for manufacturing. Dr. Hensley tested the different samples sent by the manufacturer and has selected the more superior sample to be used for production.
We are proud and excited about the future in both of these ventures and we will continue to work hard delivering quality and profitable products to our customers and shareholders.
We plan to update our shareholders soon on the finalized licensing with MyECheck, Inc. and the next steps on manufacturing Emesyl™.
Thank you for your continuing support of the Company.
CEO / President
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.